Anti-angiogenic therapies (AAT) such bevacizumab (monoclonal antibody directed against VEGF) and more recently aflibercept (VEGF-Trap) and regorafenib (oral multikinase inhibitor) have been approved in several indications in metastatic colorectal cancer, and we will discuss them further.
